Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
PBP World MeetingPBP World Meeting
Not Confirmed
Not Confirmed
23-26 March, 2026
Not Confirmed
Not Confirmed
23-24 March, 2026
European Pharma Congre...European Pharma Congress
Not Confirmed
Not Confirmed
23-24 March, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PBP World Meeting
Not Confirmed
Contact SupplierPBP World Meeting
PBP World MeetingPBP World Meeting
Industry Trade Show
Not Confirmed
23-26 March, 2026
Industry Trade Show
Not Confirmed
23-24 March, 2026
European Pharma Congre...European Pharma Congress
Industry Trade Show
Not Confirmed
23-24 March, 2026
Digital content
NEWS #PharmaBuzz
25 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/25/3244360/0/en/Helsinn-Healthcare-InVirtuoLabs-sign-a-Strategic-Collaboration-in-AI-Driven-Drug-Discovery.html
11 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/11/3236025/0/en/Helsinn-and-MagnaPharm-enter-long-term-agreement-for-AKYNZEO-and-ALOXI-across-five-Central-and-Eastern-European-countries.html
09 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/09/3234320/0/en/Helsinn-and-ESTEVE-expand-their-partnership-extending-the-Distribution-and-Licence-Agreement-for-AKYNZEO-and-ALOXI-to-Austria.html
12 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/12/3216951/0/en/Helsinn-announces-new-Executive-Leadership-Team-as-it-celebrates-50-years.html
17 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/17/3168493/0/en/AKYNZEO-demonstrates-superior-prevention-of-chemotherapy-induced-nausea-and-vomiting-compared-to-the-standard-of-care-in-patients-receiving-moderately-emetogenic-chemotherapy-with-.html
02 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/02/3054025/0/en/Helsinn-Group-submits-a-new-formulation-of-AKYNZEO-to-the-European-Medicines-Agency-EMA.html
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10877
Submission : 1994-04-11
Status : Inactive
Type : II
Certificate Number : R1-CEP 2001-348 - Rev 04
Issue Date : 2022-03-01
Type : Chemical
Substance Number : 1255
Status : Valid
Registration Number : 221MF10103
Registrant's Address : Via Industria, 24 6710 Biasca Switzerland
Initial Date of Registration : 2009-05-27
Latest Date of Registration :
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18826
Submission : 2005-09-30
Status : Active
Type : II
Certificate Number : R0-CEP 2021-328 - Rev 00
Issue Date : 2022-09-05
Type : Chemical
Substance Number : 2445
Status : Valid
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31323
Submission : 2017-03-31
Status : Active
Type : II
Registration Number : 302MF10154
Registrant's Address : Via Industria, 24 6710 Biasca Switzerland
Initial Date of Registration : 2020-12-15
Latest Date of Registration :
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-05-09
Pay. Date : 2012-12-14
DMF Number : 19918
Submission : 2006-10-30
Status : Active
Type : II
Certificate Number : R1-CEP 2004-281 - Rev 01
Issue Date : 2022-03-01
Type : Chemical
Substance Number : 1019
Status : Valid
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16063
Submission : 2002-07-19
Status : Active
Type : II
Registration Number : 220MF10072
Registrant's Address : Via Industria, 24 6710 Biasca Switzerland
Initial Date of Registration : 2008-03-14
Latest Date of Registration :
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30961
Submission : 2016-11-16
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31120
Submission : 2016-11-16
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19498
Submission : 2006-06-01
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26715
Submission : 2013-07-19
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Certificate Number : R1-CEP 2010-377 - Rev 02
Issue Date : 2022-03-01
Type : Chemical
Substance Number : 1548
Status : Valid
Registrant Name : JW Pharmaceutical Co., Ltd.
Registration Date : 2021-07-30
Registration Number : 20210730-209-J-1083
Manufacturer Name : Helsinn Advanced Synthesis SA (Helsinn/HAS)
Manufacturer Address : Via Industria 24, 6710 Biasca, Switzerland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18826
Submission : 2005-09-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31120
Submission : 2016-11-16
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30961
Submission : 2016-11-16
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6518
Submission : 1986-04-11
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19498
Submission : 2006-06-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17801
Submission : 2004-10-29
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31323
Submission : 2017-03-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5897
Submission : 1985-06-10
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-05-09
Pay. Date : 2012-12-14
DMF Number : 19918
Submission : 2006-10-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11575
Submission : 1995-07-04
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
CEP/COS
Certificate Numbers : R0-CEP 2021-328 - Rev 00
Status : Valid
Issue Date : 2022-09-05
Type : Chemical
Substance Number : 2445
CEP/COS
Certificate Numbers : R1-CEP 2004-281 - Rev 01
Status : Valid
Issue Date : 2022-03-01
Type : Chemical
Substance Number : 1019
CEP/COS
Certificate Numbers : R1-CEP 2010-377 - Rev 02
Status : Valid
Issue Date : 2022-03-01
Type : Chemical
Substance Number : 1548
CEP/COS
Certificate Numbers : R1-CEP 2001-348 - Rev 04
Status : Valid
Issue Date : 2022-03-01
Type : Chemical
Substance Number : 1255
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]JDMF
Registration Number : 220MF10072
Registrant's Address : Via Industria, 24 6710 Biasca Switzerland
Initial Date of Registration : 2008-03-14
Latest Date of Registration : 2009-06-16
Registration Number : 302MF10154
Registrant's Address : Via Industria, 24 6710 Biasca Switzerland
Initial Date of Registration : 2020-12-15
Latest Date of Registration : 2020-12-15
Registration Number : 221MF10103
Registrant's Address : Via Industria, 24 6710 Biasca Switzerland
Initial Date of Registration : 2009-05-27
Latest Date of Registration : 2009-05-27
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
As part of the agreement, Netupitant will target the Neurokinin 1 receptor to address chemotherapy-induced nausea and vomiting.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: MagnaPharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 11, 2026
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : MagnaPharm
Deal Size : Undisclosed
Deal Type : Agreement
Helsinn, MagnaPharm ink deal for AKYNZEO® and ALOXI® in Eastern Europe
Details : As part of the agreement, Netupitant will target the Neurokinin 1 receptor to address chemotherapy-induced nausea and vomiting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 11, 2026
Details:
Akynzeo (Netupitant) is a small molecule drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of chemotherapy-induced nausea and vomiting.
Lead Product(s): Netupitant,Palonosetron,Dexamethasone
Therapeutic Area: Gastroenterology Brand Name: Akynzeo
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Esteve Quimica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 09, 2026
Lead Product(s) : Netupitant,Palonosetron,Dexamethasone
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Esteve Quimica
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Helsinn, ESTEVE Extend AKYNZEO, ALOXI Deal to Austria
Details : Akynzeo (Netupitant) is a small molecule drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of chemotherapy-induced nausea and vomiting.
Product Name : Akynzeo
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 09, 2026
Details:
Akynzeo (netupitant and palonosetron) is the first and only 5-HT3 and NK1 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting in emetogenic chemotherapy.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Brand Name: Akynzeo
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 02, 2025
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Helsinn Submits New AKYNZEO Formulation to European Medicines Agency
Details : Akynzeo (netupitant and palonosetron) is the first and only 5-HT3 and NK1 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting in emetogenic chemotherapy.
Product Name : Akynzeo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 02, 2025
Details:
Fosnetupitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.
Lead Product(s): Fosnetupitant,Palonosetron
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2025
Lead Product(s) : Fosnetupitant,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fosnetupitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 01, 2025
Details:
Fosnetupitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Fosnetupitant,Netupitant,Palonosetron
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 21, 2025
Lead Product(s) : Fosnetupitant,Netupitant,Palonosetron
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fosnetupitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 21, 2025
Details:
The agreement aims for the commercialization of Akynzeo (combination of netupitant-palonosetron) and Aloxi (palonosetron) for the treatment of chemotherapy-induced nausea and vomiting in adults.
Lead Product(s): Netupitant,Dexamethasone,Palonosetron
Therapeutic Area: Gastroenterology Brand Name: Akynzeo
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Esteve Quimica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 08, 2025
Lead Product(s) : Netupitant,Dexamethasone,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Esteve Quimica
Deal Size : Undisclosed
Deal Type : Partnership
Helsinn Group & ESTEVE Renew Partnership for AKYNZEO® and ALOXI® in Germany
Details : The agreement aims for the commercialization of Akynzeo (combination of netupitant-palonosetron) and Aloxi (palonosetron) for the treatment of chemotherapy-induced nausea and vomiting in adults.
Product Name : Akynzeo
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 08, 2025
Details:
Akynzeo (fosnetupitant/palonosetron) injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting.
Lead Product(s): Netupitant,Dexamethasone,Palonosetron
Therapeutic Area: Gastroenterology Brand Name: Akynzeo
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 26, 2024
Lead Product(s) : Netupitant,Dexamethasone,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Helsinn Group launches Akynzeo injection in US market
Details : Akynzeo (fosnetupitant/palonosetron) injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting.
Product Name : Akynzeo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 26, 2024
Details:
The agreement aims to commercialise Akynzeo (combination of netupitant-palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adult patients, in UK and Ireland.
Lead Product(s): Netupitant,Dexamethasone,Palonosetron
Therapeutic Area: Gastroenterology Brand Name: Akynzeo
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Chugai Pharma Europe
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 12, 2024
Lead Product(s) : Netupitant,Dexamethasone,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Chugai Pharma Europe
Deal Size : Undisclosed
Deal Type : Agreement
Helsinn, Chugai renew partnership to sell AKYNZEO® in UK and Ireland
Details : The agreement aims to commercialise Akynzeo (combination of netupitant-palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adult patients, in UK and Ireland.
Product Name : Akynzeo
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 12, 2024
Details:
Through the agreement, Angelini Pharma will focus on commercializing Mesulid (nimesulide) in Europe. It is indicated for treating patients suffering from acute pain.
Lead Product(s): Nimesulide
Therapeutic Area: Neurology Brand Name: Mesulid
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Angelini Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 24, 2024
Lead Product(s) : Nimesulide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Angelini Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Helsinn and Angelini Renew Partnership for AULIN® and MESULID® in Central Europe
Details : Through the agreement, Angelini Pharma will focus on commercializing Mesulid (nimesulide) in Europe. It is indicated for treating patients suffering from acute pain.
Product Name : Mesulid
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 24, 2024
Details:
Netupitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Recipient: Simon Williamson Clinic
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 04, 2023
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Recipient : Simon Williamson Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy
Details : Netupitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Inspections and registrations
ABOUT THIS PAGE
Helsinn Healthcare SA is a supplier offers 19 products (APIs, Excipients or Intermediates).
Find a price of Pyridostigmine bulk with CEP, JDMF offered by Helsinn Healthcare SA
Find a price of Adapalene bulk with DMF, CEP offered by Helsinn Healthcare SA
Find a price of Fosnetupitant Chloride bulk with DMF, JDMF offered by Helsinn Healthcare SA
Find a price of Isotretinoin bulk with DMF, CEP offered by Helsinn Healthcare SA
Find a price of Palonosetron bulk with DMF, JDMF offered by Helsinn Healthcare SA
Find a price of Anamorelin HCl bulk with DMF offered by Helsinn Healthcare SA
Find a price of Dantrolene bulk with DMF offered by Helsinn Healthcare SA
Find a price of Netupitant bulk with DMF offered by Helsinn Healthcare SA
Find a price of Nimesulide bulk with CEP offered by Helsinn Healthcare SA
Find a price of Trifarotene bulk with DMF offered by Helsinn Healthcare SA
Find a price of Chlorzoxazone bulk offered by Helsinn Healthcare SA
Find a price of Guanabenz bulk offered by Helsinn Healthcare SA
Find a price of Melatonin bulk offered by Helsinn Healthcare SA
Find a price of Meso-2,3-Dimercaptosuccinic Acid bulk offered by Helsinn Healthcare SA
Find a price of Modafinil bulk offered by Helsinn Healthcare SA
Find a price of Sodium Benzoate bulk offered by Helsinn Healthcare SA
Find a price of Tramadol Hydrochloride bulk offered by Helsinn Healthcare SA
Find a price of Trospium Chloride bulk offered by Helsinn Healthcare SA
Find a price of Bosentan Hydrate bulk offered by Helsinn Healthcare SA
Share 
